Samsung Biologics plans to list in South Korea in 2016

Reuters

SEOUL (Reuters) - Samsung Biologics Co Ltd, the biopharmaceutical contract manufacturing affiliate of Samsung Group [SAGR.UL], said on Thursday that it decided to pursue an initial public offering in South Korea in 2016. The company said in a statement that it will pick advisors for the IPO in May. Analysts have estimated the company's market capitalization to be around 10 trillion won ($8.72 billion) or more. (Reporting by Joyce Lee; Editing by Ryan Woo)